Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Whole-body Magnetic Resonance Imaging in Axial Spondyloarthritis: Reduction of Sacroiliac, Spinal, and Entheseal Inflammation in a Placebo-controlled Trial of Adalimumab

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Use of the OMERACT Ultrasound Tenosynovitis Scoring System in Multicenter Clinical Trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Multiple Fractures and Impaired Bone Fracture Healing in a Patient with Pycnodysostosis and Hypophosphatasia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Imaging of Common Rheumatic Joint Diseases Affecting the Upper Limbs

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Bone turnover markers in children and adolescents with type 1 diabetes-A systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

OBJECTIVE: To investigate whether adalimumab (ADA) reduces whole-body (WB-) magnetic resonance imaging (MRI) indices for inflammation in the entheses, peripheral joints, sacroiliac joints, spine, and the entire body in patients with axial spondyloarthritis (axSpA).

METHODS: An investigator-initiated, randomized, placebo-controlled, double-blinded 48-week followup trial included 49 patients with axSpA, who had Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4.0 despite treatment with nonsteroidal antiinflammatory drugs and a clinical indication for tumor necrosis factor inhibitor treatment. Patients were randomized to subcutaneous ADA 40 mg or placebo every other week for 6 weeks; thereafter, all patients received ADA. Conventional MRI and WBMRI were performed at weeks 0, 6, 24, and 48. The primary WBMRI endpoint was the proportion of patients with an improvement in WBMRI total inflammation index above the smallest detectable change (SDC) at Week 6.

RESULTS: The primary WBMRI endpoint (improvement of SDC > 2.3) was met in 11 (44%) patients in the ADA group and 3 (13%) patients in the placebo group (p = 0.025, Fisher's exact test). The primary conventional MRI endpoint, the minimally important change in Spondyloarthritis Research Consortium of Canada Spine MRI Inflammation Index at Week 6, was achieved by 9 (36%) patients in the ADA group and 4 (17%) patients in the placebo group (p = 0.20). The primary clinical endpoint, BASDAI reduction > 50% or 2.0 at Week 24, was attained by 32 (65%) patients.

CONCLUSION: ADA provided significant reductions in WBMRI indices of peripheral, axial, and whole-body inflammation in patients with axSpA. WBMRI is promising for objective assessment and monitoring of peripheral and axial disease activity in future clinical trials.

OriginalsprogEngelsk
TidsskriftJournal of Rheumatology
Vol/bind45
Udgave nummer5
Sider (fra-til)621-629
Antal sider9
ISSN0315-162X
DOI
StatusUdgivet - 2018

ID: 55803174